At the fifth China AIDS Vaccine High-level Forum of the China Association for Science and Technology held in Shanghai, Shao Yiming, chief expert of AIDS of the Chinese Center for Disease Control and Prevention and chairman of the Executive Committee of the China AIDS Vaccine Alliance, revealed that with the support of the National Science and Technology Major Project, China ’s independent intellectual property rights are The vaccine plan has made periodic progress.
Shao Yiming introduced that the DNA-Tiantan vaccinia complex AIDS vaccine developed by a team composed of more than 10 research institutes, universities and vaccine companies has completed Phase Ib clinical trials, and good safety and specific immune responses have been observed in humans. At present, the GMP (Good Manufacturing Practice) production of the Phase II clinical trial vaccine has been completed, and an application for the trial will be submitted to the State Food and Drug Administration in the near future.
The research and development team led by the academician of the Chinese Academy of Sciences and the researcher of the Chinese Center for Disease Control and Prevention Zeng Yi has also made progress in the treatment of AIDS vaccines.
The team led by Professor Zhang Linqi, director of the AIDS Research Center of the Chinese Academy of Medical Sciences and Tsinghua University, has also made the latest progress in the development of monkey HIV vaccines using improved Tiantan vaccinia virus vectors and adenovirus vectors. It is reported that in primate trials, the combined immunization of these two candidate vaccines can effectively control the replication of pathogenic monkey HIV through the mucosal route after being challenged in the monkey body, which provides an important reference for the design of new AIDS vaccines.
The team led by Professor Kong Wei, director of the National Engineering Laboratory for AIDS Vaccines at Jilin University, focuses on the design and development of innovative AIDS vaccines, and has also made progress in preclinical research. With the support of other plans, the team is conducting a phase II clinical trial of DNA / MAV vector AIDS vaccine.
Over the past 25 years, dozens of technical routes have been adopted in the development of AIDS vaccines at home and abroad, and nearly 200 clinical trials have been carried out. In 2009, the American Institute of Health and the Thai Ministry of Health cooperated to conduct clinical trials of vaccines developed by American and French companies in Bangkok, showing a protective effect of 31.2%, becoming the first in the history of AIDS vaccine development to show that it can reduce human immunodeficiency Prophylactic vaccines for the risk of viral (HIV) infection have shown a glimmer of light for the entire field of AIDS vaccine research.
"Thailand's AIDS vaccine research advantage lies in the downstream, that is, clinical trials. Currently, two of the world's three major AIDS vaccine phase III clinical trials are conducted in Thailand. However, it took 7 years for the United States and Thailand to complete the effectiveness test of a vaccine. At this rate, in the next 20 years, only three vaccine trials can be completed. "Shao Yiming hopes that more than a dozen or more vaccines will enter clinical trials during this period, and 1-2 will be successful, so that it can be fundamentally Effectively control AIDS.
He introduced that China is an important force for AIDS vaccine research in developing countries, but it is not the same as Thailand's vaccine development strategy and route. China's vaccine research focuses on the connection between upstream and downstream, and the combination of production, education, and research, which forms a good complement to other developing countries.
The forum was sponsored by the Chinese Association of Science and Technology, undertook by the Chinese Society of Preventive Medicine, the Chinese Center for Disease Control and Prevention, STD and AIDS Prevention and Control Center, from the World Health Organization, the National Institutes of Health, the Global AIDS Vaccine Enterprise Program, the Asian AIDS Vaccine Network Alliance, and Representatives of the Ci Foundation and international and domestic experts and scholars attended the forum.
R Clip Stainless Steel,R Clip Metal Silver,Hose Clamp Stainless Steel,Hose Clamp Silver
YRX Technology (Shenzhen) Co., Ltd. , https://www.yrx-tech.com